Stockscreener 앱 받기
0.957
7.98%
-0.083
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection - Investing.com Nigeria
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection - Investing News Network
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - ACCESS Newswire
China clears kidney transplant rejection trial for CASI drug candidate - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Setup Watch: What is the long term forecast for CASI Pharmaceuticals Inc stock2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Merger Talk: Why CASI Pharmaceuticals Inc. stock is seen as undervaluedDollar Strength & Risk Controlled Daily Plans - Bộ Nội Vụ
CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing - TipRanks
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Investing News Network
CASI Pharmaceuticals : Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - marketscreener.com
Potential buyer offers 30% premium as CASI blood disorder drug shows promise - Stock Titan
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination - MSN
How CASI Pharmaceuticals Inc. stock trades during market volatility2025 Macro Impact & Safe Swing Trade Setup Alerts - Улправда
CASI Share Price | CASI Pharmaceuticals, Inc. Stock Analysis & Recommendation - MarketsMojo
Why CASI Pharmaceuticals Inc. stock could rally in 2025Portfolio Risk Summary & Accurate Entry and Exit Point Alerts - Улправда
Can CASI Pharmaceuticals Inc. stock maintain operating marginsWeekly Stock Recap & Momentum Based Trading Ideas - Улправда
CASI Pharmaceuticals closes first US$5 million tranche of convertible note financing - MSN
Will CASI Pharmaceuticals Inc. stock benefit from AI adoptionMarket Risk Analysis & Risk Managed Investment Strategies - Улправда
Aug Sentiment: Why CASI Pharmaceuticals Inc. stock could rally in 2025Market Activity Summary & Stepwise Trade Signal Guides - Улправда
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules - MSN
CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing - TipRanks
CASI Pharmaceuticals (NASDAQ: CASI) issues US$5M 12% convertible note as first tranche - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 By Investing.com - Investing.com Australia
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026 - TipRanks
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Investing News Network
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension - Investing.com
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 - Investing.com
CASI Pharmaceuticals gets extra time to stay on Nasdaq - Stock Titan
Published on: 2025-12-21 10:42:27 - Улправда
What margin trends mean for CASI Pharmaceuticals Inc. stockTake Profit & Smart Swing Trading Techniques - Улправда
Is CASI Pharmaceuticals Inc. stock a safe buy before earnings2025 Price Momentum & AI Powered Market Trend Analysis - bolumsonucanavari.com
Will CASI Pharmaceuticals Inc. stock benefit from infrastructure spendingEarnings Overview Report & Daily Market Momentum Tracking - DonanımHaber
What valuation multiples suggest for CASI Pharmaceuticals Inc. stock2025 Market WrapUp & Reliable Breakout Forecasts - DonanımHaber
Fed Watch: What analyst consensus says on CASI Pharmaceuticals Inc. stockRate Hike & Reliable Breakout Forecasts - Улправда
Aug PreEarnings: Is CASI Pharmaceuticals Inc stock a contrarian buyJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - moha.gov.vn
CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC - marketscreener.com
CASI Pharmaceuticals secures $20 million funding for transplant rejection study - Investing.com
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Investing News Network
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study - TipRanks
CASI Pharmaceuticals secures $20 million funding for transplant rejection study By Investing.com - Investing.com South Africa
CASI Pharmaceuticals (NASDAQ: CASI) plans $20 million notes to fund China AMR trial - Stock Titan
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment - Investing.com
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment By Investing.com - Investing.com Australia
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - ACCESS Newswire
4.73%
0.92%
자본화:
|
볼륨(24시간):